Emyria Limited (EMD, formerly Emerald Clinics Limited) is a clinical-stage company driving innovation in neuroscience and mental health. They achieve this through a two-pronged approach: drug development and care delivery. Their drug development arm focuses on accelerating the process of bringing new treatments to market, while their care delivery side gathers real-world data (RWD) to inform their research and improve patient outcomes. This unique combination allows Emyria to leverage real-world experience to develop new drugs more effectively, ultimately aiming to revolutionize how we approach mental health and neurological conditions.